The Latest Breaking News from Pfizer

From making her Europe’s vaccine saviour to becoming a skeleton in her closet: All the ebbs and flows in the love story between Ursula von der Leyen and big pharma Pfizer.

European court of justice says no ‘plausible explanation’ given for denying New York Times access to texts from pandemic

The EU’s top court annulled the Commission’s decision to deny the newspaper New York Times access to messages exchanged between President Ursula von der Leyen and Pfizer CEO Albert Bourla, finding that the EU executive failed to plausibly explain why it does not possess the texts.

A top European court says the European Commission was wrong to refuse the New York Times access to text messages sent between President Ursula von der Leyen and a pharmaceutical boss during the COVID-19 pandemic

A top court is to rule Wednesday on whether the EU failed the transparency test by declining to release text messages sent by Ursula von der Leyen to the head of Pfizer as the bloc tried to secure Covid vaccines.

Pharmaceutical stocks boomeranged Monday after Trump signed an executive order tying drug prices in the U.S. to international price tags.

Pfizer has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

AES Corp., Pfizer, and LyondelBasell are examples of stocks offering a high-yield dividend today and potential upside in the latter half of 2025

As the world marks World Immunization Week, attention turns once again to the lifesaving power of vaccines.

U.S. multinational activity propelled the Irish economy to 3.2% growth in the first quarter, as Trump fears come into focus.

BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.